# Preserving Lean Mass During GLP-1 Research: What the SEMALEAN Data Showed

Evidence & Research Status

Evidence LevelExtensive Human Clinical Data

FDA StatusNot FDA-approved for human use

Regulatory StatusResearch Use Only (RUO) — not for human consumption

Last UpdatedAugust 5, 2026

What This Article Covers

The single most-discussed question among researchers working with GLP-1 receptor agonists in 2026 is no longer about total weight reduction—it is about the quality of that reduction. As compounds…

Primary References [SEMALEAN study](https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70141)

Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.

The single most-discussed question among researchers working with [GLP-1 receptor](https://portaltowellness.net/glossary-glp-1-receptor/) agonists in 2026 is no longer about total weight reduction—it is about the *quality* of that reduction. As compounds like [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) , tirzepatide, and the investigational triple-agonist retatrutide move body weight down by 20% or more in trial populations, attention has shifted to what happens to lean mass along the way. New 2026 data, most notably the SEMALEAN study, is reframing that conversation.

**Related:** See a new large-scale study on GLP-1 frailty risk in older adults — [GLP-1 Frailty Risk in Older Adults](https://portaltowellness.net/research/glp-1-frailty-risk-older-adults/) .

Key Takeaways

- The SEMALEAN data specifically examined lean mass outcomes during GLP-1 research.
- Findings build on earlier body-composition substudies from the broader GLP-1 trial literature.
- Resistance training and protein intake consistently emerge as the most influential co-variables.
- Understanding lean mass preservation is increasingly central to how researchers frame GLP-1 outcomes.

## What the SEMALEAN Study Observed

Published in *Diabetes, Obesity & Metabolism* in 2026, the [SEMALEAN study](https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70141) tracked body composition in adults with obesity using semaglutide 2.4 mg. Researchers observed that total fat mass fell approximately 14% at seven months and 18% at twelve months. Lean mass declined early (roughly −3 kg at seven months) but then stabilized, rather than continuing to fall in parallel with fat.

Two functional findings stood out. Handgrip strength—a widely used proxy for overall muscle function—improved by +4.5 kg at twelve months. And the prevalence of sarcopenic obesity in the cohort dropped from 49% at baseline to 33%. In other words, the trial data indicated functional capacity moved in a favorable direction even as scale weight came down.

## Context From Earlier Body-Composition Substudies

SEMALEAN did not emerge in a vacuum. Earlier substudies gave researchers a range of reference points for how the lean-versus-fat split can vary:

| Study / Compound | Reported lean-mass share of weight lost |
| --- | --- |
| STEP-1 substudy (semaglutide) | ~40% of total weight lost from lean mass |
| SURMOUNT-1 substudy (tirzepatide) | ~25% from lean mass (≈75% from fat) |
| Semaglutide + bimagrumab (Phase 2) | ~7% lean-mass fraction |

The spread across these figures points to an important theme: the lean-mass outcome is not a fixed property of the compound. It appears to be strongly modifiable by what surrounds the intervention.

## The Variable That Kept Coming Up: Training and Protein

Across the 2026 literature, findings indicated that resistance activity and dietary protein intake track closely with lean-mass preservation. Investigators have described protein targets in the range of roughly 1.2–1.6 g/kg/day in clinical contexts, with structured resistance activity associated with better lean-mass retention. A 2026 analysis in *Cell Reports Medicine* further challenged the assumption that GLP-1 agonists preferentially degrade muscle: when total weight loss and training were accounted for, researchers observed that the lean-to-fat loss ratio was comparable to conventional caloric restriction in resistance-trained individuals.

### Open Questions for Researchers

Several questions remain unresolved in the current literature: How durable is the lean-mass stabilization SEMALEAN observed beyond twelve months? Do combination approaches (such as muscle-targeted agents alongside a GLP-1 agonist) meaningfully change functional outcomes, or only body-composition ratios? And how do these dynamics differ across age groups, given that older cohorts start from different baselines? These are active areas of investigation rather than settled findings.

## Why This Matters Now

For researchers evaluating GLP-1-class compounds, the 2026 data reframes lean mass from an unavoidable cost into a variable that appears responsive to study design. That shift matters for how experiments are structured and how outcomes are interpreted.

*All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.*

📚 Part of our [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) research guide.

Available at PTW

PTW Creatine + Hydration — Daily Support Powder

[Shop Creatine + Hydration →](https://portaltowellness.net/shop/ptw-creatine-hydration-daily-support-powder/)

### Continue Your Research

Related Articles [Wegovy Pill Total Monthly Cost, Explained](https://portaltowellness.net/research/wegovy-pill-total-monthly-cost/) [GLP-1 Prior Authorization Data](https://portaltowellness.net/research/glp-1-prior-authorization-data/)

Related Products [PTW Daily Essentials Kit — Creatine, Electrolytes and Magnesium](https://portaltowellness.net/shop/ptw-daily-essentials-kit/) [PTW Creatine + Hydration — Daily Support Powder](https://portaltowellness.net/shop/ptw-creatine-hydration-daily-support-powder/) [Semaglutide – 5mg/vial — Research Use Only](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/)

Related Research Guide [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/)

Related Category [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/)

Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/)

More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/)

---

Source: https://portaltowellness.net/research/preserving-lean-mass-glp-1-semalean-data/
Research use only. Terms: https://portaltowellness.net/research-use-only/